Trial Profile
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PRAIRI
- 01 Dec 2018 Results published in the Annals of the Rheumatic Diseases
- 03 Sep 2010 New trial record